0
0
0
Protecting Patients from Deceptive Drug Ads Act
3/13/2025, 3:21 PM
Summary of Bill S 652
Bill 119 s 652, also known as the Prescription Drug Advertising Regulation Act, aims to regulate the way prescription drugs are advertised to the public. The bill seeks to ensure that communications regarding prescription drugs are accurate and not misleading to consumers.
Under this legislation, pharmaceutical companies would be required to provide clear and transparent information about the benefits and risks of their products in any advertising or promotional materials. This includes disclosing any potential side effects or risks associated with the drug.
Additionally, the bill would establish guidelines for the use of testimonials and endorsements in prescription drug advertising. Companies would be prohibited from using misleading or false testimonials to promote their products. Overall, the goal of Bill 119 s 652 is to protect consumers from deceptive advertising practices and ensure that they have access to accurate information about prescription drugs. The bill aims to promote transparency and accountability in the pharmaceutical industry, ultimately benefiting the health and well-being of the public.
Under this legislation, pharmaceutical companies would be required to provide clear and transparent information about the benefits and risks of their products in any advertising or promotional materials. This includes disclosing any potential side effects or risks associated with the drug.
Additionally, the bill would establish guidelines for the use of testimonials and endorsements in prescription drug advertising. Companies would be prohibited from using misleading or false testimonials to promote their products. Overall, the goal of Bill 119 s 652 is to protect consumers from deceptive advertising practices and ensure that they have access to accurate information about prescription drugs. The bill aims to promote transparency and accountability in the pharmaceutical industry, ultimately benefiting the health and well-being of the public.
Read the Full Bill
Current Status of Bill S 652
Bill S 652 is currently in the status of Bill Introduced since February 20, 2025. Bill S 652 was introduced during Congress 119 and was introduced to the Senate on February 20, 2025. Bill S 652's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130) as of February 20, 2025
Bipartisan Support of Bill S 652
Total Number of Sponsors
3Democrat Sponsors
3Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
1Democrat Cosponsors
0Republican Cosponsors
1Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 652
Primary Policy Focus
HealthAlternate Title(s) of Bill S 652
A bill to provide for the regulation of certain communications regarding prescription drugs.
A bill to provide for the regulation of certain communications regarding prescription drugs.
Comments
Sponsors and Cosponsors of S 652
Latest Bills
ESTUARIES Act
Bill HR 3962December 13, 2025
Federal Maritime Commission Reauthorization Act of 2025
Bill HR 4183December 13, 2025
National Defense Authorization Act for Fiscal Year 2026
Bill S 1071December 13, 2025
Enduring Justice for Victims of Trafficking Act
Bill S 2584December 13, 2025
Technical Corrections to the Northwestern New Mexico Rural Water Projects Act, Taos Pueblo Indian Water Rights Settlement Act, and Aamodt Litigation Settlement Act
Bill S 640December 13, 2025
Incentivizing New Ventures and Economic Strength Through Capital Formation Act of 2025
Bill HR 3383December 13, 2025
BOWOW Act of 2025
Bill HR 4638December 13, 2025
Northern Mariana Islands Small Business Access Act
Bill HR 3496December 13, 2025
Wildfire Risk Evaluation Act
Bill HR 3924December 13, 2025
Energy Choice Act
Bill HR 3699December 13, 2025
